AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Rating of “Moderate Buy” by Brokerages

AnaptysBio, Inc. (NASDAQ:ANAB) has received a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $81.8182.

Several research firms have weighed in on ANAB. Leerink Partners set a $90.00 price objective on AnaptysBio in a research report on Friday, May 15th. Piper Sandler reduced their target price on shares of AnaptysBio from $95.00 to $93.00 and set an “overweight” rating for the company in a research report on Monday, May 4th. HC Wainwright began coverage on shares of AnaptysBio in a research note on Wednesday, June 10th. They issued a “buy” rating and a $95.00 price target on the stock. Weiss Ratings lowered shares of AnaptysBio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 13th. Finally, Barclays lifted their price objective on shares of AnaptysBio from $63.00 to $75.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 13th.

Institutional Investors Weigh In On AnaptysBio

Several institutional investors have recently made changes to their positions in the stock. Tema ETFs LLC increased its stake in AnaptysBio by 0.6% during the 2nd quarter. Tema ETFs LLC now owns 31,270 shares of the biotechnology company’s stock worth $2,111,000 after acquiring an additional 201 shares during the period. Los Angeles Capital Management LLC increased its position in shares of AnaptysBio by 1.5% in the fourth quarter. Los Angeles Capital Management LLC now owns 15,101 shares of the biotechnology company’s stock worth $732,000 after purchasing an additional 225 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in AnaptysBio by 24.3% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,345 shares of the biotechnology company’s stock valued at $65,000 after purchasing an additional 263 shares in the last quarter. Larson Financial Group LLC lifted its position in AnaptysBio by 21.2% during the fourth quarter. Larson Financial Group LLC now owns 1,624 shares of the biotechnology company’s stock worth $79,000 after purchasing an additional 284 shares during the period. Finally, Susquehanna Portfolio Strategies LLC lifted its position in AnaptysBio by 1.4% during the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 35,948 shares of the biotechnology company’s stock worth $1,743,000 after purchasing an additional 500 shares during the period.

AnaptysBio Stock Down 3.0%

Shares of NASDAQ:ANAB opened at $54.15 on Friday. AnaptysBio has a 12-month low of $11.40 and a 12-month high of $72.36. The stock has a market cap of $1.60 billion, a PE ratio of -50.14 and a beta of 0.68. The business has a 50 day moving average of $59.72 and a 200-day moving average of $57.30.

AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Tuesday, May 12th. The biotechnology company reported ($1.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($1.20). The firm had revenue of $25.56 million during the quarter, compared to the consensus estimate of $18.86 million. Equities research analysts expect that AnaptysBio will post -1.35 earnings per share for the current year.

AnaptysBio declared that its Board of Directors has initiated a share buyback program on Friday, March 27th that allows the company to buyback $100,000.00 billion in outstanding shares. This buyback authorization allows the biotechnology company to buy up to 5,352,316.2% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s leadership believes its stock is undervalued.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.